Ikena Oncology FY2024 EPS Estimate Boosted by HC Wainwright

Ikena Oncology, Inc. (NASDAQ:IKNA) – Research analysts at HC Wainwright boosted their FY2024 earnings per share estimates for shares of Ikena Oncology in a research note issued on Monday, November 11th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($0.95) per share for the year, up from their previous estimate of ($1.07). HC Wainwright has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Ikena Oncology’s current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Ikena Oncology’s Q4 2024 earnings at ($0.20) EPS, Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.81) EPS, FY2026 earnings at ($0.95) EPS, FY2027 earnings at ($0.93) EPS and FY2028 earnings at ($0.70) EPS.

Separately, Wedbush reiterated a “neutral” rating and issued a $2.00 price target on shares of Ikena Oncology in a research note on Thursday, November 7th.

Ikena Oncology Price Performance

NASDAQ:IKNA opened at $1.71 on Thursday. The firm has a 50-day moving average of $1.71 and a two-hundred day moving average of $1.65. The stock has a market cap of $82.52 million, a P/E ratio of -1.41 and a beta of 0.48. Ikena Oncology has a 1-year low of $1.22 and a 1-year high of $2.32.

Ikena Oncology (NASDAQ:IKNA) last announced its earnings results on Thursday, November 7th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.08.

Institutional Investors Weigh In On Ikena Oncology

Several hedge funds and other institutional investors have recently modified their holdings of IKNA. Vanguard Personalized Indexing Management LLC acquired a new position in Ikena Oncology in the second quarter worth about $30,000. BBR Partners LLC acquired a new position in shares of Ikena Oncology in the 2nd quarter worth approximately $33,000. AQR Capital Management LLC acquired a new position in shares of Ikena Oncology in the 2nd quarter worth approximately $36,000. FMR LLC increased its holdings in shares of Ikena Oncology by 94.1% in the 3rd quarter. FMR LLC now owns 38,374 shares of the company’s stock valued at $66,000 after acquiring an additional 18,607 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Ikena Oncology during the 2nd quarter valued at approximately $75,000. Institutional investors own 75.00% of the company’s stock.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.